Seeks to establish a new treatment for bullous keratopathy by producing and developing cornealendothelial replacement cells from iPS cells; advantage is a production method that can differentiate iPS cells into targetcells (CLS001) without the need for intermediate processes

In addition to advancing clinical research on CLS001, the company is currently working with several research institutions to develop treatments for new diseases by adding various genes to CLS001